<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activation of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ATP-sensitive <z:chebi fb="120" ids="26216">potassium</z:chebi> (mitoK(ATP)) channels protects the brain against ischemic or chemical challenge </plain></SENT>
<SENT sid="1" pm="."><plain>Unfortunately, the prototype mitoK(ATP) channel opener, <z:chebi fb="0" ids="4495">diazoxide</z:chebi>, has mitoK(ATP) channel-independent actions </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the effects of BMS-191095, a novel selective mitoK(ATP) channel opener, on <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Male Wister rats were subjected to 90 mins of MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>BMS-191095 (25 microg; estimated brain concentration of 40 micromol/L) or vehicle was infused intraventricularly before the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the effects of BMS-191095 on plasma and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potentials and reactive oxygen species (ROS) production in cultured neurons were examined </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, we determined the effects of BMS-191095 on cerebral blood flow (CBF) and <z:chebi fb="120" ids="26216">potassium</z:chebi> currents in cerebrovascular myocytes </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with BMS-191095 24 h before the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reduced total <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 32% and cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 38% </plain></SENT>
<SENT sid="8" pm="."><plain>However, BMS-191095 administered 30 or 60 mins before MCAO had no effect </plain></SENT>
<SENT sid="9" pm="."><plain>The protective effects of BMS-191095 were prevented by co-treatment with 5-hydroxydecanoate (5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), a mitoK(ATP) channel <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>In cultured neurons, BMS-191095 (40 micromol/L) depolarized the mitochondria without affecting ROS levels, and this effect was inhibited by 5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>BMS-191095, similar to the vehicle, caused an unexplained but modest reduction in the CBF </plain></SENT>
<SENT sid="12" pm="."><plain>Importantly, BMS-191095 did not affect either the <z:chebi fb="120" ids="26216">potassium</z:chebi> currents in cerebrovascular myocytes or the plasma membrane potential of neurons </plain></SENT>
<SENT sid="13" pm="."><plain>Thus, BMS-191095 afforded protection against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> by delayed preconditioning via selective opening of mitoK(ATP) channels and without ROS generation </plain></SENT>
</text></document>